PharmaFocus Today – Page 127 – media

The first major pharmaceutical merger in 2025

On January 13, Johnson & Johnson announced that it had reached a final agreement with Intra-Cellular Therapies to acquire all outstanding shares of the latter at a price of US$132 per share, with a total transaction value of approximately US$14.6 billion. Intra-Cellular Therapies is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of central nervous system (CNS) diseases. Its core asset is a once-daily oral antipsychotic product Caplyta (lumateperone). The drug is a 5-hydroxytryptamine 2A (5-HT2A) receptor antagonist and dopamine receptor D2 modulator, first developed by Bristol-Myers Squibb (BMS). In 2015, Intra-Cellular Therapie obtained a license from BMS for global development. In December 2019, Caplyta was approved by the FDA for the treatment of adult patients with schizophrenia, and in December 2021 it was approved for the adjuvant treatment of depressive episodes associated with bipolar disorder type I or type II (bipolar depression). In ...
- Source: drugdu
- 333
- January 20, 2025
Over 4.4 billion US dollars! GLP-1 opens a new chapter

There is no doubt that this is the era of GLP-1. Recently, in less than a month, three GLP-1 transactions were concluded one after another, involving an amount exceeding US$4.4 billion. First, Merck introduced the small molecule GLP-1RA HS-10535 from Hansoh Pharmaceuticals, and then Jixing Pharmaceutical introduced the global (except Greater China) development and commercialization rights of the oral small molecule GLP-1RA CX11 from Wingtech Pharmaceuticals. Recently, Verdiva Bio, an overseas Biotech company, has introduced the rights to once-weekly oral inoglutide from Xianweida Biotech. Among these transactions, a significant trend has attracted attention-the oral dosage form of GLP-1 drugs has become the focus of competition among pharmaceutical companies. Both emerging biotechnology companies and established pharmaceutical giants are all focusing their R&D resources on oral GLP-1 drugs, and a fierce competition around oral dosage forms has begun. The advantages are fully demonstrated . Currently, the mainstream GLP-1 drugs are mainly injections. ...
- Source: drugdu
- 379
- January 20, 2025
Legendary Biology’s 11 early cell therapy pipelines are advancing; Lilly GLP-1 drug sales fall short of expectations | Medical Early Reference

NO.1 Legendary Biology’s 11 Early Cell Therapy Pipelines are Advancing On January 15th Beijing time, Dr. Huang Ying, CEO of Legendary Biotech, gave a speech at the 43rd J.P. Morgan Healthcare Annual Meeting (JPM). Huang Ying introduced the progress of Legendary Biotech’s core products, core technology platforms, and research pipelines. The company has currently established a CAR-T cell therapy product portfolio that includes 11 early-stage research and development pipelines, covering multiple fields such as hematological malignancies, solid tumors, and autoimmune diseases. Comment: The report shows that Legendary Biology is advancing multiple research pipelines for autologous cell therapy/allogeneic cell therapy. These investigational therapies have a wide range of indications, not limited to multiple myeloma, but also include solid tumors such as autoimmune diseases, non Hodgkin lymphoma, small cell lung cancer, acute lymphoblastic leukemia, and hematological tumors. NO.2 Sanofi/Regenerator IL-33 monoclonal antibody has been re approved for clinical use in China The ...
- Source: drugdu
- 285
- January 17, 2025
Sinopharm and Beite Pharmaceutical have reached a strategic cooperation framework for overseas commercialization

Recently, Sinovac Biotech Co., Ltd. (hereinafter referred to as “Sinovac Biotech”) and Chengdu Beite Pharmaceutical Co., Ltd. (hereinafter referred to as “Beite Pharmaceutical”) signed an intention agreement, intending to achieve overseas commercial strategic cooperation for some of Beite Pharmaceutical’s formulation products. Both parties plan to adopt various cooperation models, including but not limited to overseas commercialization rights for specific products and regions, localized technology transfer in overseas markets, and cooperative development. According to the list of products that can be cooperated with provided by Beite Pharmaceutical, after both parties sign a formal cooperation agreement, Sinopharm will have the commercial cooperation rights of the products in the designated overseas regions. Beite Pharmaceutical is a high-tech enterprise specializing in pharmaceutical innovation and the R&D, production and sales of high-quality drugs. It has long been committed to the four major R&D directions of characteristic APIs, high-end generic drugs, innovative drugs and new ...
- Source: drugdu
- 278
- January 17, 2025
Medtronic, lock in the next acquisition target

On January 13, 2025, global medical technology giant Medtronic (NYSE: MDT) announced that it had reached an exclusive distribution agreement with Contego Medical in the United States. In addition, Medtronic’s additional investment in Contego and the option to acquire the company are also important components of this agreement. 01. Exclusive distribution and locked acquisition According to the agreement signed with Contego Medical, Medtronic will become the sole distributor of Contego’s existing commercial product portfolio in the US market. Contego Medical focuses on providing innovative revascularization treatment options aimed at treating carotid and peripheral vascular diseases. Its product portfolio has gained widespread recognition in the medical industry for its unique technology and clinical efficacy. This agreement specifically covers Contego’s recently approved Neuroguard IEP 3-in-1 carotid stent system by the US Food and Drug Administration (FDA). The system integrates high-performance stents, posterior dilation balloons, and embolization protection (IEP) filters, providing safer and ...
- Source: drugdu
- 386
- January 17, 2025
Johnson&Johnson’s 1 medical device approved for market launch

Recently, Johnson&Johnson MedTech announced its Dual Energy ThermoCool SmartTouch ™ The SF catheter has obtained European CE certification and is used to treat arrhythmias such as atrial fibrillation. It is understood that this product is the second CE approved dual energy ablation catheter. The first one is Medtronic’s Sphere-9 ablation catheter, which is a multifunctional, high-density (HD) mapping and pulsed field (PF) and radiofrequency (RF) ablation catheter used to treat persistent atrial fibrillation and tricuspid valve isthmus dependent atrial flutter. It was approved by the FDA in October 2024. The second dual energy ablation catheter Dual Energy ThermoCool SmartTouch ™ The SF catheter is an ablation catheter with a porous head end saline infusion, which combines Thermocol smartpouch technology with SF catheter porous infusion technology. This product combines contact force sensing and advanced porous tip ablation technology, and adds stronger operability and torque to achieve excellent control. It is understood ...
- Source: drugdu
- 260
- January 17, 2025
Net loss after deducting non-recurring items is expected to be 155 million to 220 million yuan in 2024, and revenue and profit of vaccine segment will drop sharply

Wantai Bio announced on January 15 that it expects to achieve net profit attributable to the parent company’s owners of 86 million to 120 million yuan in 2024, a year-on-year decrease of 90.38% to 93.11%; it is expected that the net profit attributable to the parent company’s owners after deducting non-recurring gains and losses in 2024 will be -155 million to -220 million yuan. During the reporting period, the company’s vaccine segment was affected by market adjustments, government centralized procurement and the expansion of the age of the nine-valent HPV vaccine, and sales were not as expected. The revenue and profit of the vaccine segment dropped sharply, resulting in a net loss. At the same time, the company promoted international market sales through multiple methods and channels, and overseas operating income increased by 55% compared with the same period last year. The diagnostics segment benefited from the accelerated advancement of ...
- Source: drugdu
- 216
- January 17, 2025
Full-year sales forecast lowered by $1 billion, what happened to the Chinese factory of the star COVID-19 vaccine company Moderna?

On January 13, American vaccine manufacturer Moderna lowered its 2025 sales forecast by $1 billion to cut costs. The company’s stock price plummeted 17% at the close of the day. Moderna’s latest forecast is that revenue in 2025 will be between $1.5 billion and $2.5 billion, a sharp drop from the $2.5 billion to $3.5 billion forecast in September last year. Moderna said that most of these sales will come from sales of the COVID-19 vaccine and the newly launched respiratory syncytial virus (RSV) vaccine in the second half of 2025. In 2024, the company’s revenue from these two vaccines is about $3 billion. Demand for Moderna’s COVID-19 vaccine is falling rapidly. The company’s COVID-19 vaccine revenue reached $18 billion and $6.7 billion in 2022 and 2023, respectively. Other COVID-19 vaccine manufacturers, Novavax and BioNTech, are also actively seeking transformation. Moderna Chief Financial Officer Jamey Mock said that the company ...
- Source: drugdu
- 239
- January 17, 2025
Bio-Vaccine ETF (562860) rose 2.28%, and three major driving factors promoted the long-term improvement of the vaccine industry

As of 11:25 on January 14, 2025, the CSI Vaccine and Biotechnology Index rose strongly by 2.20%, with constituent stocks BeiGene rising 9.38%, Hualan Vaccine rising 4.95%, Digene Pharmaceuticals rising 4.86%, and Zhixiang Jintai, Dongbao Bio and other stocks following the rise. Bio-Vaccine ETF (562860) rose 2.28%, and the intraday turnover reached 11.6195 million yuan, with a turnover rate of 4.12%. In terms of shares, the latest shares of Bio-Vaccine ETF reached 485 million, a record high in the past month. It is worth noting that the valuation of the CSI Vaccine and Biotechnology Index tracked by the fund is at a historical low, with the latest price-to-book ratio PB being 2.64 times, which is lower than the index’s 89.23% of the time in the past three years, and the valuation cost-effectiveness is outstanding. Data shows that as of December 31, 2024, the top ten weighted stocks of the CSI ...
- Source: drugdu
- 192
- January 17, 2025
Sinovac exclusively won the bid for the Chilean influenza vaccine project. The first batch of vaccines will be sent to Chile tomorrow

On January 14, at the press conference of SINOVAC’s winning bid for the Chilean project, Meng Weining, Vice President and Head of International Business of Sinovac, introduced that on January 10, the trivalent influenza vaccine Anerlife® produced by Beijing Sinovac Biological Products Co., Ltd. under SINOVAC Sinovac exclusively won the bid for the Chilean government’s 2025 annual influenza vaccine global tender. The first batch of vaccines will be sent to Chile on January 15. Meng Weining said that this winning bid means that the influenza vaccines that the Chilean government will provide free of charge to the people of the country in 2025 will all be provided by Sinovac. This is an important breakthrough for Sinovac in the influenza vaccine market in the southern hemisphere, breaking the monopoly of multinational companies in the Chilean market for many years. According to reports, since 2020, Sinovac has supplied a total of 22 ...
- Source: drugdu
- 241
- January 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.